Drug
Methylprednisolone or equivalent
Methylprednisolone or equivalent is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
1(25%)
Results Posted
100%(2 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_4
1
25%
Ph phase_1
2
50%
Ph phase_3
1
25%
Phase Distribution
2
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Terminated(1)
Detailed Status
Completed2
Active, not recruiting1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
66.7%
Most Advanced
Phase 4
Trials by Phase
Phase 12 (50.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
Trials by Status
completed250%
active_not_recruiting125%
terminated125%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_3
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
NCT04270409
terminatedphase_1
Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation
NCT04294459
completedphase_1
Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
NCT00078559
completedphase_4
Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation
NCT00717379
Clinical Trials (4)
Showing 4 of 4 trials
NCT04270409Phase 3
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
NCT04294459Phase 1
Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation
NCT00078559Phase 1
Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
NCT00717379Phase 4
Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4